{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:05:48Z","timestamp":1792112748335,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III"},{"name":"Ministerio de Ciencia e Innovaci\u00f3n"},{"name":"05\/2346"},{"name":"Fundaci\u00f3n Alicia Koplowitz"},{"name":"Mutua Madrile\u00f1a"},{"name":"Ministerio de Ciencia e Innovaci\u00f3n"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.clnu.2011.03.007","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T17:06:23Z","timestamp":1303146383000},"page":"616-623","source":"Crossref","is-referenced-by-count":32,"title":["Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics"],"prefix":"10.1016","volume":"30","author":[{"given":"Cristina","family":"Cuerda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Merchan-Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Leiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Gir\u00e1ldez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bret\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Camblor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garc\u00eda-Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dul\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Desco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2011.03.007_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1176\/ps.2006.57.12.1693","article-title":"Antipsychotic use and expenditure in the United States","volume":"57","author":"Aparasu","year":"2006","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clnu.2011.03.007_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0028-1103293","article-title":"Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund","volume":"42","author":"Weinbrenner","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.clnu.2011.03.007_bib4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/ps.2008.59.5.554","article-title":"Use of antipsychotic drugs among Dutch youths between 1997 and 2005","volume":"59","author":"Kalverdijk","year":"2008","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clnu.2011.03.007_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsichotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a metaanalysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib6","first-page":"161","article-title":"CATIE and CUtLASS: can we handle the truth?","volume":"192","author":"Lewis","year":"2008","journal-title":"B\u00a0J Psych"},{"key":"10.1016\/j.clnu.2011.03.007_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1176\/ps.2008.59.5.523","article-title":"Lessons to take home from CATIE","volume":"59","author":"Carpenter","year":"2008","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clnu.2011.03.007_bib8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"Clark","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2011.03.007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clnu.2011.03.007_bib10","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1463-1326.2004.00413.x","article-title":"Antipsychotic-induced weight gain","volume":"7","author":"Goudie","year":"2005","journal-title":"Diabetes obesity Metabolism"},{"key":"10.1016\/j.clnu.2011.03.007_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","article-title":"Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine","volume":"159","author":"Gothelf","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","article-title":"Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study","volume":"90","author":"Bobes","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-9964(99)00191-7","article-title":"Mortality and causes of death in schizophrenia in Stockholm county Sweden","volume":"45","author":"Osby","year":"2000","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnu.2011.03.007_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns","volume":"19","author":"Vitiello","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib18","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clnu.2011.03.007_bib19","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","article-title":"Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics","volume":"69","author":"Fraguas","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.jcp.0000177549.36585.29","article-title":"A\u00a0comparison of the effects of olanzapine and risperidone versus placebo on eating behaviours","volume":"25","author":"Roerig","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jada.2005.01.005","article-title":"Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication","volume":"105","author":"Sharpe","year":"2005","journal-title":"J\u00a0Am Diet Assoc"},{"key":"10.1016\/j.clnu.2011.03.007_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nut.2008.08.006","article-title":"Comparison of predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine","volume":"25","author":"Skouroliakou","year":"2009","journal-title":"Nutrition"},{"key":"10.1016\/j.clnu.2011.03.007_bib25","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/j.1440-1614.2006.01888.x","article-title":"Energy expenditure and physical activity in clozapine use: implications for weight management","volume":"40","author":"Sharpe","year":"2006","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-2002-31521","article-title":"Decrease of energy expenditure causes weight increase in olanzapine treatment- a case study","volume":"35","author":"Virkkunen","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0920-9964(03)00190-7","article-title":"Clozapine's effects on body weight and resting metabolic rate: a case series","volume":"66","author":"Procyshyn","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib28","first-page":"159","article-title":"Atypical antipsychotic medications and symptoms of psychotic illness do not affect resting metabolic rate in people with mental illness","volume":"7","author":"Sharpe","year":"2006","journal-title":"Obes Reviews"},{"key":"10.1016\/j.clnu.2011.03.007_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2007.0138","article-title":"Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach","volume":"18","author":"Castro-Fornieles","year":"2008","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib30","series-title":"Nutritional assessment","first-page":"223","article-title":"Anthropometry","author":"Lee","year":"1996"},{"key":"10.1016\/j.clnu.2011.03.007_bib31","first-page":"371","article-title":"Study of resting energy expenditure in anorexia nervosa, agreement between indirect calorimetry and several equations","volume":"20","author":"Cuerda","year":"2005","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.clnu.2011.03.007_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ajcn\/37.3.461","article-title":"A\u00a0method to assess energy expenditure in children and adults","volume":"37","author":"Bouchard","year":"1983","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2011.03.007_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib34","series-title":"A\u00a0biometric study of basal metabolism in man","author":"Harris","year":"1919"},{"key":"10.1016\/j.clnu.2011.03.007_bib35","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/ajcn\/34.9.1816","article-title":"Energy expenditure and fat-free mass in men and women","volume":"34","author":"Webb","year":"1981","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2011.03.007_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/ajcn\/73.3.511","article-title":"The importance of clinical research: the role of thermogenesis in human obesity","volume":"73","author":"Schoeller","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2011.03.007_bib37","first-page":"E357","article-title":"Energy expenditure during carbohydrate overfeeding in opbese and nonobese adolescents","volume":"256","author":"Bandini","year":"1989","journal-title":"Am J Physiol"},{"issue":"Suppl.","key":"10.1016\/j.clnu.2011.03.007_bib38","doi-asserted-by":"crossref","first-page":"956S","DOI":"10.1093\/ajcn\/68.4.956S","article-title":"Balancing energy expenditure and body weight","volume":"68","author":"Schoeller","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2011.03.007_bib39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199503093321001","article-title":"Changes in energy expenditure resulting from altered body weight","volume":"332","author":"Leibel","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnu.2011.03.007_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0447.2005.00700.x","article-title":"Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls","volume":"114","author":"Nilsson","year":"2005","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clnu.2011.03.007_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib42","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1176\/ajp.2006.163.7.1276","article-title":"Association of initial antipsychotic response to clozapine and long-term weight gain","volume":"163","author":"Bai","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0269881105056647","article-title":"Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia","volume":"20","author":"Hosojima","year":"2006","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.psyneuen.2004.05.008","article-title":"Olanzapine increases plasma ghrelin level in patients with schizophrenia","volume":"30","author":"Murashita","year":"2005","journal-title":"Psychoneuroendocrinol"},{"key":"10.1016\/j.clnu.2011.03.007_bib47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1819.2007.01610.x","article-title":"Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia","volume":"61","author":"Murashita","year":"2007","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clnu.2011.03.007_bib48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/01.chi.0000170552.15798.dd","article-title":"Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study","volume":"44","author":"Sporn","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment","volume":"28","author":"P\u00e9rez-Iglesias","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-200401000-00007","article-title":"Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study","volume":"19","author":"Togo","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.jcp.0000218404.64619.52","article-title":"Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia","volume":"26","author":"Richards","year":"2006","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0b013e31819b95fc","article-title":"Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions","volume":"29","author":"Birkenaes","year":"2009","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.clnu.2011.03.007_bib53","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.schres.2008.09.008","article-title":"A\u00a0cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder","volume":"106","author":"Hanssens","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib54","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4088\/JCP.v68n1202","article-title":"Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia","volume":"68","author":"Bai","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.clnu.2011.03.007_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.014","article-title":"Association of adiponectin and metabolic syndrome among patients taking antipsychotics for schizophrenia: a cohort study","volume":"111","author":"Bai","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clnu.2011.03.007_bib56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.diabet.2008.03.003","article-title":"Insulin sensitivity, adjusted \u03b2-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study","volume":"34","author":"Oriot","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clnu.2011.03.007_bib57","first-page":"573","article-title":"Comparison of clinical body composition methods in people taking weight-inducing atypical antipsychotic medications","volume":"17","author":"Sharpe","year":"2008","journal-title":"Asia Pac J Clin Nutr"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561411000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561411000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T03:57:15Z","timestamp":1560139035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561411000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0261561411000598"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2011.03.007","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}